European Medicines Agency: leave the UK but remain the same.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?Journal of the Royal Society of Medicine · 2020
   Review
2. HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?The European journal of health economics : HEPAC : health economics in prevention and care · 2020
   Article
3. Health technology assessment for pharmaceutical regulation in the European Union: do we need another body?Journal of the Royal Society of Medicine · 2020
   Article
4. Pharmaceutical pricing conundrum: time to get rid of it?The European journal of health economics : HEPAC : health economics in prevention and care · 2018
   Article
5. Competition in pharmaceuticals: more product- than price-oriented?The European journal of health economics : HEPAC : health economics in prevention and care · 2018
   Article
6. Market approval for drugs in the EU: time to change direction?The European journal of health economics : HEPAC : health economics in prevention and care · 2017
   Article
7. Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?Journal of the Royal Society of Medicine · 2017
   Article
8. Drug approval and research assessment: arguments for reform.Journal of the Royal Society of Medicine · 2016
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as